Copyright
©The Author(s) 2024.
World J Orthop. Dec 18, 2024; 15(12): 1155-1163
Published online Dec 18, 2024. doi: 10.5312/wjo.v15.i12.1155
Published online Dec 18, 2024. doi: 10.5312/wjo.v15.i12.1155
Table 5 Univariate analysis following the division of patients into three groups based on tumor proportion score and immune checkpoint inhibitors use
n | Median OS | 95%CI | P value | |
TPS ≥ 50% and ICI use | 12 | 54 | 3-not censored | 0.079 |
TPS ≤ 49% or not tested and ICI use | 16 | 19 | 8-not censored | |
No use of ICI | 17 | 13 | 5–16 |
- Citation: Ishibashi Y, Kobayashi H, Ando T, Okajima K, Oki T, Tsuda Y, Shinoda Y, Sawada R, Tanaka S. Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study. World J Orthop 2024; 15(12): 1155-1163
- URL: https://www.wjgnet.com/2218-5836/full/v15/i12/1155.htm
- DOI: https://dx.doi.org/10.5312/wjo.v15.i12.1155